Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
The deepCDR engine combines deep sequencing and deep learning methods with a proprietary mammalian display process to select from a wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles
She replaces Victoria Tabiner, who is stepping down after 10 years at Sygnature
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
Research collaboration covers multiple antibody research programs
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
Subscribe To Our Newsletter & Stay Updated
